• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: UNKNOWN HSV 2 IGG TEST; ENZYME LINKED IMMUNOSORBENT ASSAY, HERPES SIMPLEX VIRUS, HSV-2

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

UNKNOWN HSV 2 IGG TEST; ENZYME LINKED IMMUNOSORBENT ASSAY, HERPES SIMPLEX VIRUS, HSV-2 Back to Search Results
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 09/17/2023
Event Type  malfunction  
Event Description
I took a hsv2 (herpes simplex virus) test which uses igg (immunoglobulin g) and received an initial low positive result.I then took a confirmation test (inhibition assay) and was normal (not detected).Meaning, my first result was a false positive.9/17 test from labcorp 9/26 test from quest.Resulted on 10/10 (took 14 days to result).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
HSV 2 IGG TEST
Type of Device
ENZYME LINKED IMMUNOSORBENT ASSAY, HERPES SIMPLEX VIRUS, HSV-2
Manufacturer (Section D)
UNKNOWN
MDR Report Key18487211
MDR Text Key332783667
Report NumberMW5150106
Device Sequence Number1
Product Code MYF
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Voluntary
Reporter Occupation Patient
Type of Report Initial
Report Date 01/05/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Was Device Available for Evaluation? No
Initial Date Manufacturer Received Not provided
Initial Date FDA Received01/09/2024
Patient Sequence Number1
Treatment
CLARITIN PRN (PRO RE NETA / AS NEEDED) ALLERGIES.
Patient Outcome(s) Other;
Patient Age27 YR
Patient SexMale
Patient Weight68 KG
Patient EthnicityNon Hispanic
Patient RaceWhite
-
-